Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Talimogene Laherparepvec Response in Recurrent Melanoma During Corticosteroid Replacement for Immune Checkpoint Inhibitor–Induced Adrenal Insufficiency: A Case Report. Local targets link to admitted publications; unresolved targets remain external evidence.
Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomized controlled trials
10.1016/s1470-2045(23)00524-7 · 2024 · External reference
Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens
10.1001/jamaoncol.2017.3064 · 2018 · External reference
Talimogene laherparepvec improves durable response rate in patients with advanced melanoma
10.1200/jco.2014.58.3377 · 2015 · External reference
First oncolytic virus approved for melanoma immunotherapy
10.1080/2162402x.2015.1115641 · 2016 · External reference
Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
10.1186/s40425-016-0158-5 · 2016 · External reference
Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma
10.1200/jco.2017.73.7379 · 2018 · External reference
Use of talimogene laherparepvec to treat cutaneous squamous cell carcinoma in a renal transplant patient
10.1159/000530851 · 2023 · External reference
Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report
10.1111/bjd.17783 · 2019 · External reference
